Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Mohsin El Amrani"'
Autor:
Roselie Achten, Judith Thijs, Marlot van derWal, Chantal vanLuijk, Matthijs vanLuin, Mohsin el Amrani, Edward Knol, Eveline Delemarre, Constance den Hartog Jager, Marlies deGraaf, Daphne Bakker, Joke deBoer, Femke vanWijk, Marjolein deBruin‐Weller
Publikováno v:
Clinical and Translational Allergy, Vol 13, Iss 1, Pp n/a-n/a (2023)
Abstract Background The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings
Externí odkaz:
https://doaj.org/article/4a18129e6a18458bb626727c686b33dd
Autor:
Erin H. Smeijsters, Kim C. M. van der Elst, Amy Visch, Camiel Göbel, Floris C. Loeff, Theo Rispens, Alwin D. R. Huitema, Matthijs van Luin, Mohsin El Amrani
Publikováno v:
Pharmaceutics, Vol 15, Iss 5, p 1477 (2023)
Monoclonal antibodies (mAbs), such as infliximab, are important treatment options for different diseases. Immunogenicity is a major risk, resulting in anti-drug antibodies (ADAs), being associated with adverse events and loss of response, influencing
Externí odkaz:
https://doaj.org/article/17e81377605e42de912eb2b322fe36bf
Autor:
Anouk A. M. T. Donners, László Gerencsér, Kim C. M. van derElst, Toine C. G. Egberts, Moniek P. M. deMaat, Albert Huisman, Rolf T. Urbanus, Mohsin El Amrani
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 4, Pp n/a-n/a (2022)
Abstract Background Emicizumab is a new treatment option for people with hemophilia A. Emicizumab was approved with a body‐weight‐based dosage regimen, without laboratory monitoring requirements. Guidelines, however, recommend measuring emicizuma
Externí odkaz:
https://doaj.org/article/2430ded2cc43412e95a67340e7f21f87
Autor:
Rong-Long Chen, Li-Hua Fang, Xin-Yi Yang, Mohsin El Amrani, Esther Veronique Uijtendaal, Yen-Fu Chen, Wei-Chi Ku
Publikováno v:
Pharmaceuticals, Vol 14, Iss 7, p 613 (2021)
Busulfan has been used as a conditioning regimen in allogeneic hematopoietic cell stem transplantation (HSCT). Owing to a large inter-individual variation in pharmacokinetics, therapeutic drug monitoring (TDM)-guided busulfan dosing is necessary to r
Externí odkaz:
https://doaj.org/article/2abc79dd6f3144afa33fb187d9b0f1a7
Autor:
Mohsin El Amrani, Camiel Göbel, Annelies C. Egas, Stefan Nierkens, C. Erik Hack, Alwin D.R. Huitema, Erik M. van Maarseveen
Publikováno v:
Journal of Translational Autoimmunity, Vol 1, Iss , Pp - (2019)
Background: The development of anti-drug antibodies (ADA) in patients treated with therapeutic proteins can result in treatment failure. The clinically most relevant fraction of these antibodies are the neutralizing anti-drug antibodies (NAb) that bl
Externí odkaz:
https://doaj.org/article/233fb804500e42faa13ec88e51fbb4c0
Autor:
Coco Dekkers, Mohsin El Amrani, Matthijs van Luin, Daphne Bakker, Leon Plusjé, Femke van Wijk, Marjolein de Bruin‐Weller
Publikováno v:
Journal of the European Academy of Dermatology and Venereology.
Autor:
Coco Dekkers, M.Marlot van der Wal, Mohsin El Amrani, Matthijs van Luin, Daphne S. Bakker, Marjolein de Bruin-Weller, Femke van Wijk
Publikováno v:
Journal of Investigative Dermatology.
Autor:
Femke van Wijk, Marjolein de Bruin-Weller, Mohsin El Amrani, Matthijs van Luin, Daphne Bakker, Marlot van der Wal, Coco Dekkers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7829a4a2c6b0946326bb8e5c2e9e5c86
https://doi.org/10.26226/m.62fa008e5b695e001a542075
https://doi.org/10.26226/m.62fa008e5b695e001a542075
Autor:
Marjolein de Bruin-Weller, Joke de Boer, Daphne Bakker, Marlies de Graaf, Eveline Delemarre, Mohsin El Amrani, Matthijs van Luin, Femke van Wijk, Chantal van Luijk, Judith Thijs, Roselie Achten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1187d2c1ab5106e7b2245e3cf3e79ed6
https://doi.org/10.26226/m.62fa0091165d7b0019592aa8
https://doi.org/10.26226/m.62fa0091165d7b0019592aa8
Autor:
C. Erik Hack, Sabine M Bosman, Mohsin El Amrani, Erik M. van Maarseveen, Alwin D. R. Huitema, Annelies C. Egas
Publikováno v:
Therapeutic Drug Monitoring, 41(5), 640. Lippincott Williams and Wilkins
BACKGROUND: Therapeutic drug monitoring of tumor necrosis factor alpha (TNF-α) inhibitors such as adalimumab (ADM) and infliximab (IFX) is considered of added value for patients with systemic inflammatory diseases. In contrast to enzyme-linked immun